Me either. Just as well the US $ strengthened
before settlement. Yes we had a win on exchange
rate. No I didn’t look at details but saw $13.5 m
as a cost on books.
I am pleased with TXMD products, but still believe
we are serving two masters . Both the owner of
Annorexia IP ( 15 % ) and our ongoing costs to TXMD.
To me this is messy. We don’t know the relationship
between those two companies. As with most of our
dealings there are questions ( grey areas ). Remember
Hadrian some individuals have done very nicely out
of Mayne whilst retail shareholders have been stripped.
OK for recent holders to me it appears could be a
winner , but the market in general is most apprehensive.
. Why is that ? Our shareprice has halved since doing
deal. Why ?? Because like myself there are obviously
many awaiting some real changes in bottom line figures
and not words . Some consolidation and real progress
towards profitability. A few directors owning shares
wouldn't go unnoticed either.
Also re the $40 million We all know lawyers are expensive, but to just say is not good enough imo.
Did we get our monies worth ? Did we ?
That is a lot for a very short period. I still question
it. Anyway we are all wishing and hoping this is
a new culture and there are some professional
experienced innovators leading us and to prosperity
with Mayne.
- Forums
- ASX - By Stock
- MYX
- Ann: Update on convertible note arrangements with Rubric Capital
MYX
mayne pharma group limited
Add to My Watchlist
0.60%
!
$5.05

Ann: Update on convertible note arrangements with Rubric Capital, page-13
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.05 |
Change
0.030(0.60%) |
Mkt cap ! $405.4M |
Open | High | Low | Value | Volume |
$5.00 | $5.05 | $4.94 | $258.0K | 51.74K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
19 | 2416 | $5.03 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.05 | 3911 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 2416 | 5.030 |
8 | 2023 | 5.020 |
3 | 1086 | 5.010 |
5 | 1987 | 5.000 |
4 | 4580 | 4.990 |
Price($) | Vol. | No. |
---|---|---|
5.050 | 5571 | 4 |
5.060 | 5932 | 6 |
5.070 | 970 | 2 |
5.080 | 3607 | 3 |
5.090 | 1225 | 3 |
Last trade - 12.13pm 26/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online